Evaluation of the potential herb-drug interaction between Bojungikki-tang and PD-L1 immunotherapy in a syngeneic mouse model

• Ngā kaituhi matua: Sung-Yoon Yang (Author), Jin-Mu Yi (Author), Jaemoo Chun (Author), Seongwon Park (Author), Tham Thi Bui (Author), Hwi-Yeol Yun (Author), Jung-Woo Chae (Author), Mi-Kyung Jeong (Author)
• Hōputu: Pukapuka
• I whakaputaina: Frontiers Media S.A., 2023-05-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Atezolizumab (a PD-L1 inhibitor) has shown remarkable efficacy and tolerability in various cancer types. Despite its efficacy and safety, atezolizumab monotherapy has limitations, such as acquired resistance and adverse events. Bojungikki-tang (BJIKT) is an herbal decoction widely prescribed in Asia...